Ibrutinib Combination Therapy in Transplant Ineligible Individuals With Newly Diagnosed Primary CNS Lymphoma
Status:
Recruiting
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
This study is being done to answer the following question: Can the addition of a new drug to
the usual treatment lower the chance of primary central nervous system lymphoma growing or
spreading?
This study is being done to find out if this approach is better or worse than the usual
approach for this type of cancer. The usual approach is defined as the care most people get
for Primary Central Nervous System Lymphoma (PCNSL).